The Event. The Q2 10-Q landed this morning. Cash and cash equivalents: $125.9M at June 30, down from $169.5M at March 31 and $209.9M at year-end. Net cash used in operations for the first half: $86.2M. The going-concern language I flagged in May is still there, verbatim, in both the liquidity note and the risk factors.
The Reaction. The stock is at $39.98, down 8.5% from the $43.68 where I wrote the May update. The market has spent three months doing nothing while the balance sheet did quite a lot.
The Reality. Kodiak is not slowing down to conserve cash. They’re accelerating. R&D jumped to $56.1M in Q2 from $42.8M a year ago, and they just dosed the first patients in a brand-new ~910-patient Phase 3 (ALTO) in diabetic macular edema. That is not the spending pattern of a company waiting to see if DAYBREAK works. That’s the spending pattern of a company that already knows how it plans to fund the next eighteen months.
The Receipts
Cash: $125.9M, runway “into 2027.” Same hedge as last quarter — sufficient for current and planned operations into 2027, but explicitly not sufficient for the 12 months following the filing date. The implication: the financing window is now, not later.
Burn accelerated, not decelerated. Q2 operating cash use ran roughly $43.1M (the half totaled $86.2M against Q1’s $40.3M). Net loss for the quarter was $65.6M vs. $54.3M a year ago. In my May piece I noted Q1’s $40.3M was “slightly better” than the ~$46M/quarter I’d modeled. That relief has evaporated.
The R&D mix flipped completely. Tarcocimab (Zenkuda) spend fell to $9.4M for the quarter, while KSI-501 hit $12.7M (from $3.9M) and KSI-101 hit $12.3M (from $1.4M — an 8.5x increase). Why it matters: the money has fully migrated from the de-risked asset to the two unproven ones. The lead program is essentially finished spending; the platform bets are consuming everything.
ALTO is now enrolling. A new registrational Phase 3 of KSI-501 vs. aflibercept in DME, ~910 patients, randomized 5:3:5, followed ~96 weeks, with a superiority primary endpoint on BCVA at the Week 48/52 average. First patients dosed in Q2.
PEAK Cohort 1 enrollment complete. All 300 patients in for Pivotal Analysis 1, topline December 2026. Cohort 2 (600 subjects across PEAK and PINNACLE) completes enrollment in 4Q 2026, reading out 2Q 2027.
DAYBREAK is still September 2026. No slippage. Both Zenkuda and KSI-501 arms vs. aflibercept, one-year primary endpoint.
Share count: 62,830,860 at June 30 (62,849,457 as of August 6), up from 61,758,454 at year-end. All of it option exercises and ESPP — no equity raise yet. Financing activities generated a grand total of $3.6M in the half.
A small real-estate tell. In July, Kodiak terminated the remaining eight months of the 1200 Page Mill lease (and the sublease with it) in exchange for an option on a different building. Housekeeping, but it’s consistent with a company trimming fixed costs while the clinical spend balloons.
